GHRP-2 5mg

GHRP-2 5mg — Research Overview

GHRP-2 (Growth Hormone Releasing Peptide-2; Pralmorelin) is a synthetic hexapeptide GH secretagogue. It is a second-generation upgrade to GHRP-6, designed with a modified amino acid sequence to trigger a more robust GH-releasing effect. Its specific structure — D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH₂ — gives it a tighter GHS-R1a binding affinity than GHRP-6, which results in a more potent GH secretory response per molar dose. Researchers recognise GHRP-2 as one of the most powerful synthetic GH secretagogues available; it easily beats GHRP-6 in GH-releasing potency while keeping a broadly similar pharmacological mechanism.

Mechanism of Action

GHRP-2 triggers GHS-R1a via the same Gq/PLC/IP3-dependent pathway observed with GHRP-6 and similar GH secretagogues. Since it possesses a stronger receptor binding affinity than GHRP-6, it produces a steeper dose-response curve for GH secretion in preclinical models. Like other GHS-R1a agonists, GHRP-2 can stimulate cortisol and prolactin release by cross-activating corticotrophs and lactotrophs, though these effects are not usually as significant as the GH response itself. This non-selective hormonal co-stimulation is why many research teams prefer the cleaner selectivity profile of Ipamorelin 2mg when a study design requires isolated GH manipulation.

When you pair GHRP-2 with GHRH analogues, it triggers a synergistic GH release through the same complementary mechanism found in other GHS/GHRH combinations. Research involving GHRP-2 alongside CJC-1295 W/O DAC or Sermorelin 2mg usually shows much larger GH peaks than when using either peptide on its own. This happens because the GHRH pathway ramps up somatotroph responsiveness while the GHS-R1a signal acts as the actual trigger for vesicle release.

Research Context

GHRP-2’s gained significant research attention as a diagnostic agent for pituitary GH reserve. Its potent GH-stimulating action reliably distinguishes patients with intact pituitary function from those with GH deficiency. As a pharmacological probe for somatotroph responsiveness, it’s been used in clinical studies examining GH secretory dynamics in normal aging, obesity, hypothyroidism, and other states where GH pulsatility is altered.

Researchers have looked into GHRP-2’s direct tissue effects in preclinical settings, finding they’re quite similar to what’s seen with GHRP-6 and hexarelin, especially in cardiac protection models. There’s evidence from rodent models showing GHRP-2 can shrink infarct size and ease post-ischemic cardiac dysfunction. It doesn’t just rely on GH secretion either; it likely involves direct GHS-R1a signalling within the heart tissue itself.

Comparative pharmacology often groups GHRP-2, GHRP-6 5mg, and Hexarelin 2mg as a trio of GHS-R1a agonists. They’ve got graded potency and slightly different selectivity profiles, allowing for structure-activity relationship analyses of GHS pharmacology.

Laboratory Handling

GHRP-2 5mg arrives as a lyophilised white powder. For research, investigators usually reconstitute it with sterile bacteriostatic water. Once in solution, the peptide should be kept at 4°C and used within a few days; for longer storage, freezing aliquots at −20°C is most effective. An HPLC purity of ≥98% is ensured as standard. It is important for research teams to avoid repeated freeze-thaw cycles or exposure to heat to maintain the stability of the peptide.

For research purposes only. Not for clinical use or human administration.

References

• Arvat E, et al. GHRP-2 potently stimulates GH secretion in normal subjects. J Endocrinol Invest. 1993;16(5):347–351.
• Ghigo E, et al. Growth hormone-releasing peptides: clinical and basic aspects. Horm Res. 1999;51(Suppl 3):84–91.
• Torsello A, et al. Cardiovascular effects of growth hormone secretagogues. J Endocrinol Invest. 1999;22(5 Suppl):33–40.
• Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest. 2003;26(9):799–813.

Comparative Notes

GHRP-2 is one of the most reliable pharmacological GH stimulation agents for pituitary testing because it’s so potent. That said, it also triggers cortisol and prolactin release, so any GH assay using it needs to measure those hormones too if you want to fully characterise the pituitary response. If your study needs clean GH specificity, you might want to combine GHRP-2 with a somatostatin antagonist or switch to ipamorelin to isolate that GH signal. Choosing the right secretagogue for your experimental design really comes down to understanding these trade-offs.

For more information on GHRP-2 peptide please visit Wikipedia.